Centessa Pharmaceuticals — Investor Presentation (January 2025)
25 slides from Centessa Pharmaceuticals's investor presentation, Jan 8, 2025

Slide 1: January 2025 Corporate Overview
January 2025 Corporate Overview

Slide 2: Disclaimer and Forward Looking Statements
2 DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential

Slide 3: Discovering and Developing Transformational Medicines for Patients
3 Discovering and Developing Transformational Medicines for Patients OUR MISSION Centessa reported $518.4 million in cash, cash equivalents and short-term investments as of September 30, 2024. Cash runway estimated into mid-2027. Potential best-in-class / first-in-class orexin receptor 2 (OX2R) agon

Slide 4: 2025 Focused Execution
2025 Focused Execution ORX750 Phase 2a data in patients with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 Clinical data in acutely sleep-deprived healthy volunteers expected in 2025 ORX489 E

Slide 5: OX2R agonists have the potential to transform the standard of care
OX2R agonists have the potential to transform the standard of care for individuals with sleep-wake, neurological, neurodegenerative and psychiatric disorders 5

Slide 6: Orexin System is Implicated in Numerous Therapeutic Areas
Orexin System is Implicated in Numerous Therapeutic Areas Orexin: a key signaling neuropeptide triggering a cascade of neurotransmitter release 6 Wakefulness Cognition Orexin (hypothalamus) Dopamine (Ventral tegmental area) Serotonin (Raphe nuclei) Acetylcholine (Basal forebrain) Sources: Pizza, F e

Slide 7: Candidate Selection Criteria: Best-in-Class Profile
Candidate Selection Criteria: Best-in-Class Profile • Highly potent and highly selective • Optimal predicted PK profile • Low predicted human doses • Fast onset of action OX2R agonist Orexin-A: Highly Validated Pathway Proprietary Structure Based Drug Design Pipeline of Highly Potent, Selective OX2R

Slide 8: Positioned to be Potential Best-in-Class / First-in-Class in OX2R Agonist Therapeutics
Positioned to be Potential Best-in-Class / First-in-Class in Emerging Category of OX2R Agonist Therapeutics ORX750 for the treatment of NT1, NT2 and IH ORX142 for the treatment of neurological, neurodegenerative and psychiatric disorders Earlier stage OX2R agonists and therapeutics for additional po

Slide 9: Broad and Rapidly Advancing OX2R Pipeline
Broad and Rapidly Advancing OX2R Pipeline Centessa also has multiple early-stage assets including the LockBody® Technology Platform. ASSET DISEASE/CONDITION MECHANISM PRE-CLINICAL PHASE 1 PHASE 2 ORX750 Narcolepsy Type 1 (NT1) OXR2 Agonist ORX750 Narcolepsy Type 2 (NT2) OXR2 Agonist ORX750 Idiopathi

Slide 10: Potential $15B+ Market Opportunity Across Multiple Therapeutic Areas
Source: Evaluate Pharma 2030 projected sales for narcolepsy – sales are not risk adjusted; projections for other disorders based on internal market research. Potential $15B+ Market Opportunity Across Multiple Therapeutic Areas Sleep-Wake Disorders NT1, NT2, IH $5B+ potential market size Additional O

Slide 11: ORX750: Potential to Redefine the Standard of Care for Sleep-Wake Disorders
11 ORX750: Potential to Redefine the Standard of Care for Patients with Sleep-Wake Disorders Advancing Phase 2a studies in patients with NT1, NT2 and IH; Data expected across all three indications in 2025 High unmet medical need in NT1, NT2 and IH Proof-of-concept achieved and asset clinically deris

Slide 12: ORX750 Interim Phase 1 Data Supports Potential Best-in-Class Profile
ORX750 Phase 1 Interim Data Supports Potential Best-in-Class Profile for the Treatment of NT1, NT2 and IH Summary of Interim Phase 1 Data *MWT is an established registrational and objective endpoint in EDS in sleep-wake disorders. The Phase 1 clinical study of ORX750 evaluates the safety, tolerabili

Slide 13: ORX750 Demonstrated Dose-Dependent Improvements in Mean Sleep Latency
ORX750 Demonstrated Dose-Dependent and Significant Improvements in Mean Sleep Latency ORX750 LS Mean (95% CI) Sleep Latency (Minutes) Placebo LS Mean (95% CI) Sleep Latency (Minutes) LS Mean Difference Compared to Placebo (95% CI) p-value 1.0 mg (n=8) 18 (12, 23) 10 (4, 15) 8 (0, 16) p=0.04 2.5 mg (

Slide 14: ORX750 Phase 1 Safety: Treatment-Emergent Adverse Events
SAD Cohorts MAD Cohorts Placebo (n=15) ORX750 1.0 mg (n=9) ORX750 2.0 mg (n=9) ORX750 2.5 mg (n=9) ORX750 3.5 mg (n=9) ORX750 5.0 mg (n=9) Placebo (n=6) ORX750 2.0 mg (n=8) ORX750 3.0 mg (n=8) ORX750 4.0 mg (n=8) Any TEAE, n (%) 4 (27) 3 (33) 3 (33) 1 (11) 0 3 (33) 3 (50) 4 (50) 4 (50) 6 (75) Relate

Slide 15: Phase 2a Study of ORX750 in NT1, NT2, IH
PHASE 2a STUDY Phase 2a study of ORX750 in patients with NT1, NT2, IH underway Data expected in 2025 Evaluate safety, tolerability, and PK in NT1, NT2, and IH patients Efficacy assessments will evaluate excessive daytime sleepiness using the Maintenance of Wakefulness Test (MWT)* and Epworth Sleepin

Slide 16: Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750
PHASE 2a STUDY Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750 in Patients with NT1, NT2, and IH is Underway Data expected in all three indications in 2025 Innovative design with potential to enable well-powered and efficient data generation All patients to receive ORX750 for at

Slide 17: OX2R Agonist Program
OX2R AGONIST PROGRAM ORX750 Initiated Phase 2a study in patients with NT1, NT2, and IH; Data expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 IND-enabling studies ongoing; Clinical data in acutely sleep- deprived healthy volunteers expected in 2025 ORX489 Entering IND-enablin

Slide 18: LockBody Technology Platform
18 LockBody Technology Platform

Slide 19: LockBody Technology Platform aims to redefine immuno-oncology treatment
LockBody Technology Platform aims to redefine immuno-oncology treatment Novel pharmacology combining tumor enrichment with activation of effector function Designed as single agent systemic treatment Potential wide therapeutic index1 1. LB101 in-vivo preclinical data: MC38 hPD-L1+ syngeneic model in

Slide 20: Locked Configuration MOA: LockBody LB101
Locked Configuration MOA LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 20

Slide 21: Unlocked Configuration MOA: LockBody LB101
Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody MOA 21

Slide 22: Observed to be Well Tolerated in Non-Human Primates
Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50 mg/kg Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates. No anemia/ thrombocytopenia No weight loss No change in red blood cell or hemoglobin 22 PRECLINICAL DATA

Slide 23: LB101 is in a Phase 1/2a first-in-human clinical trial
LB101 is in a Phase 1/2a first-in-human clinical trial 23

Slide 24: Discovering and Developing Transformational Medicines for Patients
24 Discovering and Developing Transformational Medicines for Patients OUR MISSION Centessa reported $518.4 million in cash, cash equivalents and short-term investments as of September 30, 2024. Cash runway estimated into mid-2027. Potential best-in-class / first-in-class orexin receptor 2 (OX2R) ago

Slide 25: Centessa
>< CENTESSA
Source: SEC EDGAR · 8-K filed Jan 8, 2025
More decks from Centessa Pharmaceuticals PLC
Investor Presentation (November 2025)21 slides · Nov 5, 2025
Investor Presentation (November 2024)29 slides · Nov 12, 2024
Investor Presentation (September 2024)39 slides · Sep 10, 2024
Investor Presentation (April 2024)37 slides · Apr 22, 2024
Technical Presentation (February 2024)14 slides · Feb 9, 2024
Investor Presentation (January 2024)31 slides · Jan 9, 2024